The Bull Rankings scorecard — our quality-growth score is 85.6 / 100, built from three pillars scored 0–100: Quality 66, Growth 100, Value 95 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free cash flow shrinking about 6% next year, then recovering toward 3% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
The latest quarter was a barnburner — adjusted EPS of $2.21 crushed the $2.05 consensus while sales landed at $266.044M, beating the $260.128M estimate. That revenue growth of 30.9% over the past year, paired with an 11% profit margin and an 18.1% ROE, is the kind of operating leverage that turns top-line surges into real earnings power. Our Bull Rankings model sees it clearly: the Growth pillar clocks in at a perfect 100, the strongest of the three. Yet the price-to-earnings of 16.5× and a PEG of 0.38 price in far less than that growth. The reverse-DCF is even more revealing: the current price embeds roughly –6% annual free-cash-flow growth (in year one, recovering toward 3% a year by year ten), a stark mismatch to the 30.9% revenue surge.
What the business actually is
ANI is a full-service biopharma that designs, manufactures, and markets branded and generic pharmaceuticals. Its portfolio runs from injectables and softgel capsules to Cortrophin gel, ILUVIEN, and YUTIQ. It also produces oral solids, semi-solids, liquids, topicals, controlled substances, and potent products. Customers include national wholesalers, specialty pharmacies, retail chains, mail-order houses, group purchasing organizations, and hospitals. Cortrophin gel is the current growth engine, while ILUVIEN and YUTIQ anchor high-margin specialty niches.
Why it can (or can't) keep compounding
An ROE of 18.1% shows capital is being put to work. The 11% profit margin, alongside $173M in trailing free-cash-flow, proves the business can reinvest without strangling cash generation. The Bull Rankings model’s strongest pillar — Growth at 100 — reflects the 30.9% year-over-year revenue climb, largely driven by Cortrophin’s record quarter. ANI’s moat is operational: a diversified manufacturing platform capable of handling potent and controlled substances, a capability hard to replicate quickly. That infrastructure lets ANI capture niche, higher-margin contracts while still scaling generic volumes. A beta of 0.46 means the stock has moved little with the broader market.
The valuation question
At $75.76 the stock trades at 16.5× earnings and 1.8× sales, comfortably below specialty-pharma peers. The PEG of 0.38 implies analysts expect earnings growth well above what the multiple reflects. The reverse-DCF, however, tells a different story: the price already embeds roughly –6% annual free-cash-flow growth (in year one, recovering toward 3% a year by year ten). In other words, the market is discounting future cash generation far more than the fundamentals justify. Analyst targets sit at $108.38, with a range of $90–$121, reinforcing that the upside is already on many watchlists, but the current price still leaves a sizable gap to those expectations.
The bear case
The weakest pillar in our model is Quality, scoring 66, which signals execution risk. Debt-to-equity stands at 1.05, a level that could strain cash flow if rates rise or if new product launches require funding. The earnings call confirmed forward guidance was trimmed, and shares fell 7.6% on the news despite the beat. If revenue growth slips below 30.9% or if margin pressure erodes the 11% profit rate, the free-cash-flow outlook could indeed turn negative, validating the reverse-DCF’s pessimistic assumption.
What would change our mind
A sustained revenue growth rate above 30.9% for two consecutive quarters would keep the Growth pillar at the top and force the market to reprice the free-cash-flow trajectory upward. A reduction of debt-to-equity below 1.0 would improve balance-sheet resilience and ease cash-flow concerns. Finally, an EPS beat that pushes the P/E below 15× while maintaining the current margin would widen the gap between the price and the growth story even further. Any of these moves would shift the balance toward a stronger bullish conviction.